EuroPCR Late-Breaking Clinical Trial Data Finds Effectivenes

Late-breaking clinical data presented at EuroPCR 2023 in Paris demonstrated Elixir Medical’s DynamX Bioadaptor restores vessel motion and function with better effectiveness at 12 months compared to a leading drug-eluting stent (DES).

Related Keywords

California , United States , Paris , France General , France , Milpitas , Motasim Sirhan , Development Of The Dynamx Bioadaptor , Elixir Medical Corporation , Elixir Medical , Dynamx Coronary Drug Eluting Bioadaptor , Resolute Onyx Drug Eluting Stent , Target Lesion Failure , Resolute Onyx , Dynamx Bioadaptor , Clinical Safety , Dynamx Coronary Bioadaptor System ,